Association of Chronic Insomnia With Mortality and Adverse Renal Outcomes

Jun Ling Lu, Amado X. Freire, M. Molnár, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy

Research output: Contribution to journalArticle

3 Citations (Scopus)


Objective: To examine whether chronic insomnia is associated with an increased risk of adverse renal outcomes and all-cause mortality. Patients and Methods: We examined associations of chronic insomnia (defined as the presence of both International Classification of Diseases, Ninth Revision codes 307.42, 307.49, and 780.52 and long-term use of insomnia medications) with adverse renal outcomes (end-stage renal disease, incidence of estimated glomerular filtration rate [eGFR] ≤45 mL/min per 1.73 m2, and eGFR slopes <−3.0 mL/min per 1.73 m2 per year) and all-cause mortality in a national cohort of 1,639,090 US veterans by using Cox proportional hazards and logistic regression models with multivariable adjustments. Results: A total of 36,741 patients (2.24%) had chronic insomnia; 32,985 (89.8%) were male and 28,090 (76.5%) were white, with a mean baseline eGFR of 84.1±16.4 mL/min per 1.73 m2. Chronic insomnia was associated with a significantly higher risk of eGFR 45 mL/min per 1.73 m2 or less (multivariable-adjusted hazard ratio [HR], 1.39; 95% CI, 1.34-1.44; P<.001), end-stage renal disease (HR, 1.25; 95% CI, 0.81-1.93; P=.32), and rapid loss of kidney function (odds ratio, 1.07; 95% CI, 1.03-1.12; P=.002). Chronic insomnia was not associated with a higher risk of all-cause mortality (HR, 1.00; 95% CI, 0.97-1.03; P=.99). Conclusion: Chronic insomnia is associated with a higher risk of development and progression of kidney disease. Further studies are needed to establish the underlying mechanisms of action and to determine whether treatment of insomnia could be beneficial to prevent deteriorating kidney function.

Original languageEnglish
JournalMayo Clinic Proceedings
Publication statusAccepted/In press - Jan 1 2018


ASJC Scopus subject areas

  • Medicine(all)

Cite this